Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLR203701
- Development stage
- Unknown
- Lead developer
- Gan & Lee Pharmaceuticals
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
GLR203701: sourced facts only. name: "In VCaP, LNCaP and 22RV1 cells, GLR203701 could degrade more than 90% of AR, with half-maximal degradation concentration (DC50) < 10 nM." [DOI:10.1158/1538-7445.am2025-7022]; target: "In VCaP, LNCaP and 22RV1 cells, GLR203701 could degrade more than 90% of AR, with half-maximal degradation concentration (DC50) < 10 nM." [DOI:10.1158/1538-7445.am2025-7022]; developer: "Gan & Lee Pharmaceuticals, Beijing, China." [DOI:10.1158/1538-7445.am2025-7022]; modality: "Recently, our drug discovery campaign led to the discovery of a potent AR PROTAC, named GLR203701." [DOI:10.1158/1538-7445.am2025-7022]
Beyond the preview
Go deeper on GLR203701.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLR203701.